Brief: Belite Bio Announces Positive Topline Results From Pivotal Global, Phase 3 Dragon Trial Of Tinlarebant
01/12/2025 11:26
Dec 1 (Reuters) - Belite Bio Inc BLTE.O: NEW HOPE FOR PEOPLE LIVING WITH A DISEASE ONCE DEEMED UNTREATABLE: BELITE BIO ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PIVOTAL GLOBAL, PHASE 3 DRAGON TRIAL OF TINLAREBANT IN ADOLESCENTS WITH STARGARDT DISEASE BELITE BIO INC - TO FILE NDA WITH FDA IN 1H 2026 BELITE BIO INC: TINLAREBANT MET PRIMARY EFFICACY ENDPOINT IN A GLOBAL PHASE 3 TRIAL BELITE BIO INC: TINLAREBANT WAS WELL TOLERATED THROUGHOUT TRIAL Source text: ID:nGNX7FD3q4 Further company coverage: BLTE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses